Treatment of LFA-1 Associated Disorders with Increasing Doses of LFA-1 Antagonist
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
1 . A method for treating dermatitis, comprising
administering to a mammal in need thereof a first conditioning dose of an antibody or a receptor binding fragment thereof which binds CD11a; and
administering a second therapeutic dose of the antibody, wherein the second dose is higher than the first dose.
2 . The method of claim 1 wherein the antibody is a humanized antibody.
3 . The method of claim 1 , further comprising administering a third therapeutic dose, wherein the third dose is higher than or equal to the second dose.
4 . The method of claim 1 , further comprising administering a fourth therapeutic dose, wherein the fourth dose is higher than or equal to the third dose.
5 . The method of claim 1 or claim 2 , wherein administration is intravenous or subcutaneous.
6 . The method of claim 1 or claim 2 , wherein administration is not more than once per week.
7 . The method of claim 1 or claim 2 , wherein the antibody or receptor binding fragment thereof is non-lymphocyte depleting.
8 . The method of claim 7 , wherein the antibody or receptor binding fragment thereof is non-T-cell depleting.
9 . The method of claim 1 or claim 2 , wherein the first conditioning dose is 0.7 mg/kg and the second therapeutic dose is 1.0 mg/kg.
10 . The method of claim 1 or claim 2 , wherein the first conditioning dose is 0.7 mg/kg and the second therapeutic dose is 2.0 mg/kg.
11 . A method for treating graft versus host or host versus graft transplant rejection, comprising
administering to a mammal in need thereof a first conditioning dose of an antibody or a receptor binding fragment thereof which binds CD11a; and
administering a second therapeutic dose of the antibody, wherein the second dose is higher than the first dose.
12 . The method of claim 11 wherein the antibody is a humanized antibody.
13 . The method of claim 11 , further comprising administering a third therapeutic dose, wherein the third dose is higher than or equal to the second dose.
14 . The method of claim 11 , further comprising administering a fourth therapeutic dose, wherein the fourth dose is higher than or equal to the third dose.
15 . The method of claim 11 or claim 12 , wherein administration is intravenous or subcutaneous.
16 . The method of claim 11 or claim 12 , wherein administration is not more than once per week.
17 . The method of claim 11 or claim 12 , wherein the antibody or receptor binding fragment thereof is non-lymphocyte depleting.
18 . The method of claim 17 , wherein the antibody or receptor binding fragment thereof is non-T-cell depleting.
19 . The method of claim 11 or claim 12 , wherein the first conditioning dose is 0.7 mg/kg and the second therapeutic dose is 1.0 mg/kg.
20 . The method of claim 11 or claim 12 , wherein the first conditioning dose is 0.7 mg/kg and the second therapeutic dose is 2.0 mg/kg.